Research programme: oxygen radical scavanger therapeutics - MitoImmune Therapeutics
Latest Information Update: 28 Jan 2025
Price :
$50 *
At a glance
- Originator MitoImmune Therapeutics
- Class Anti-inflammatories; Antifibrotics; Hepatoprotectants
- Mechanism of Action Antioxidants; Oxygen radical scavengers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammatory bowel diseases
Most Recent Events
- 28 Jan 2025 No recent reports of development identified for research development in Inflammatory-bowel-diseases in South Korea